BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

Author's Avatar
Aug 22, 2022

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society (“ERS”) International Congress 2022, being held in Barcelona, Spain from September 4-6, 2022.